Regeneron shares data for multiple myeloma treatment
Betsy Goodfellow | December 8, 2023 | News story | Medical Communications | Cancer, Oncology, Regeneron, clinical trial
Regeneron Pharmaceuticals has announced positive data from the pivotal LINKER-MM1 trial which assessed linvoseltamab as a treatment for patients with relapsed/refractory (R/R) multiple myeloma (MM).
The trial demonstrated a 71% objective response rate, with 46% achieving a complete response or better after 11 months of median follow up.
All patients treated with the 200mg dose experienced adverse events, with 85% experiencing Grade ≥3 events, the most common being cytokine release syndrome.
This data is expected to be submitted to the relevant regulatory authorities, including the US Food and Drug Administration (FDA) this year.
L Andres Sirulnik, MD PhD, senior vice president, Translational and Clinical Sciences, Haematology at Regeneron, commented: “MM remains an incurable disease, in which patients endure cycles of relapse and remission, resulting in a critical need for innovative medicines. With longer follow-up data on linvoseltamab, we’re seeing deep and durable responses with a complete response rate nearing 50% in a difficult-to-treat patient population who had received a median of five prior lines of therapy. Furthermore, in our trial, the regimen had a short monitoring time and a convenient, response-adapted administration schedule that enabled deep responders to go from every two-week to every four-week dosing. This regimen saved time for clinicians and patients, underscoring the potential for linvoseltamab as a patient-centric option in R/R MM.”
Betsy Goodfellow
Related Content
Sanofi and Regeneron’s Dupixent receives CHMP recommendation for chronic spontaneous urticaria
Sanofi and Regeneron have received a positive opinion from the European Medicines Agency’s (EMA) Committee …
UCB announces first-in-patient trial success for galvokimig in atopic dermatitis
UCB has reported positive early clinical trial results for galvokimig, an investigational therapy for adults …
FDA approves Wegovy for treatment of MASH in adults with liver fibrosis
The US Food and Drug Administration (FDA) has granted accelerated approval for Wegovy (semaglutide) as …
